Table 2.
Comparison of any chemotherapy identified by SEER POC data and Medicare claims during various post-diagnosis periods for selected cancer sites and year
| Source reporting receipt of chemotherapy | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| POC=Yes, Med=Yes |
POC=No, Med=No |
POC=Yes, Med=No |
POC=No, Med=Yes |
Kappa (%) (95% CI) |
Se (%) (95% CI) |
Sp (%) (95% CI)† |
PPV (%) (95% CI) |
NPV (%) (95% CI) |
|
| Breast (2000 and 2005) | |||||||||
| 2 months | 11 | 259 | 46 | 2 | 27 (7, 46) | 19 (10, 32) | 99 (97, 100) | 85 (55, 98) | 85 (80, 89) |
| 4 months | 45 | 252 | 13 | 6 | 79 (70, 88) | 78 (65, 87) | 98 (95, 99) | 88 (76, 96) | 95 (92, 97) |
| 6 months | 48 | 247 | 9 | 7 | 83 (74, 91) | 84 (72, 93) | 97 (94, 99) | 87 (76, 95) | 96 (93, 98) |
| 8 months | 48 | 245 | 7 | 7 | 84 (77, 92) | 87 (76, 95) | 97 (94, 99) | 87 (76, 95) | 97 (94, 99) |
| 10 months | 48 | 240 | 7 | 8 | 83 (75, 92) | 87 (76, 95) | 97 (94, 99) | 86 (74, 94) | 97 (94, 99) |
| 12 months | 49 | 240 | 6 | 8 | 85 (77, 93) | 89 (78, 96) | 97 (94, 99) | 86 (74, 94) | 98 (95, 99) |
| Colorectal (2000) | |||||||||
| 2 months | 45 | 78 | 61 | 3 | 36 (23, 49) | 42 (33, 52) | 96 (90, 99) | 94 (83, 99) | 56 (47, 65) |
| 4 months | 90 | 66 | 15 | 6 | 76 (66, 86) | 86 (78, 92) | 92 (83, 97) | 94 (87, 98) | 81 (71, 89) |
| 6 months | 92 | 60 | 12 | 7 | 77 (67, 87) | 88 (81, 94) | 90 (80, 96) | 93 (86, 97) | 83 (73, 91) |
| 8 months | 93 | 53 | 8 | 8 | 79 (69, 89) | 92 (85, 97) | 87 (76, 94) | 92 (85, 97) | 87 (76, 94) |
| 10 months | 91 | 50 | 7 | 8 | 79 (69, 89) | 93 (86, 97) | 86 (75, 94) | 92 (85, 96) | 88 (76, 95) |
| 12 months | 88 | 48 | 7 | 10 | 76 (65, 87) | 93 (85, 97) | 83 (71, 91) | 90 (82, 95) | 87 (76, 95) |
| Colorectal (2005) | |||||||||
| 2 months | 70 | 172 | 115 | 3 | 36 (26, 45) | 38 (31, 45) | 98 (95, 100) | 96 (88, 99) | 60 (54, 66) |
| 4 months | 145 | 157 | 34 | 8 | 76 (69, 83) | 81 (74, 86) | 95 (91, 98) | 95 (90, 98) | 82 (76, 87) |
| 6 months | 154 | 151 | 23 | 10 | 81 (74, 87) | 87 (81, 92) | 94 (89, 97) | 94 (89, 97) | 87 (81, 91) |
| 8 months | 153 | 145 | 19 | 10 | 82 (76, 88) | 89 (83, 93) | 94 (88, 97) | 94 (89, 97) | 88 (83, 93) |
| 10 months | 148 | 144 | 17 | 10 | 83 (77, 89) | 90 (84, 94) | 94 (88, 97) | 94 (89, 97) | 89 (84, 94) |
| 12 months | 147 | 140 | 15 | 9 | 85 (79, 90) | 91 (85, 95) | 94 (89, 97) | 94 (89, 97) | 90 (85, 94) |
| Non-Small Cell Lung (2005) | |||||||||
| 2 months | 61 | 149 | 60 | 5 | 50 (39, 60) | 50 (41, 60) | 97 (93, 99) | 92 (83, 97) | 71 (65, 77) |
| 4 months | 95 | 111 | 17 | 6 | 80 (72, 88) | 85 (77, 91) | 95 (89, 98) | 94 (88, 98) | 87 (80, 92) |
| 6 months | 89 | 95 | 8 | 5 | 87 (80, 94) | 92 (84, 96) | 95 (89, 98) | 95 (88, 98) | 92 (85, 97) |
| 8 months | 77 | 87 | 8 | 5 | 85 (78, 93) | 91 (82, 96) | 95 (88, 98) | 94 (86, 98) | 92 (84, 96) |
| 10 months | 70 | 76 | 6 | 4 | 87 (79, 95) | 92 (84, 97) | 95 (88, 99) | 95 (87, 99) | 93 (85, 97) |
| 12 months | 64 | 72 | 5 | 6 | 85 (76, 94) | 93 (84, 98) | 92 (84, 97) | 91 (82, 97) | 94 (85, 98) |
| Ovary (2002)* | |||||||||
| 2 months | 96 | 45 | 48 | 3 | 46 (33, 59) | 67 (58, 74) | 94 (83, 99) | 97 (91, 99) | 48 (38, 59) |
| 4 months | 129 | 36 | 9 | 6 | 77 (66, 88) | 93 (88, 97) | 86 (71, 95) | 96 (91, 98) | 80 (65, 90) |
| 6 months | 125 | 32 | 5 | 5 | 83 (72, 93) | 96 (91, 99) | 86 (71, 95) | 96 (91, 99) | 86 (71, 95) |
| 8 months | 119 | 26 | 6 | 6 | 76 (64, 89) | 95 (90, 98) | 81 (64, 93) | 95 (90, 98) | 81 (64, 93) |
| 10 months | 112 | 25 | 5 | 6 | 77 (64, 90) | 96 (90, 99) | 81 (63, 93) | 95 (89, 98) | 83 (65, 94) |
| 12 months | 109 | 21 | 3 | 6 | 78 (65, 92) | 97 (92, 99) | 78 (58, 91) | 95 (89, 98) | 88 (68, 97) |
POC = Patterns of Care, Med=Medicare, Se = Sensitivity, Sp = Specificity, PPV = Positive predictive value, NPV = Negative predictive value
*
Three ovarian cancer patients did not report any chemotherapy treatment data in POC and were removed from analysis.
†
Exact binomial 95% confidence intervals are rounded to the nearest digit. Therefore, none of the upper limits is exactly 100%.